Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics.
Business Model:
Revenue: $0
Employees: 51-200
Myogen was acquired by
Gilead Sciences.
The acquisition happend on 2006-10-02.
Details of the transaction were not public
Address:
City: Westminster
State: Colorado
Zip:
Country: United States
Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. They believe that our advanced understanding of the biology of cardiovascular disease combined with their clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
10/30/2003
IPO Valuation:
$350M
Ticker Symbol:
MYOG
IPO Price:
$14/share
Amount Raised:
$70M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|